Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study

BACKGROUND: Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a favourable option for patients with migraine who experience distressful headache disability and fail to respond to traditional preventive treatment options. However, since CGRPmAb has been available for only 2 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Ihara, Keiko, Ohtani, Seiya, Watanabe, Narumi, Takahashi, Nobuyuki, Miyazaki, Naoki, Ishizuchi, Kei, Hori, Satoko, Takemura, Ryo, Nakahara, Jin, Takizawa, Tsubasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996919/
https://www.ncbi.nlm.nih.gov/pubmed/36890436
http://dx.doi.org/10.1186/s10194-023-01556-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996919/
https://www.ncbi.nlm.nih.gov/pubmed/36890436
http://dx.doi.org/10.1186/s10194-023-01556-7

Ejemplares similares